Business
MetaStat, Inc. Announces Positive Results of a MenaCalc(TM) Prognostic Study of Axillary Node-Negative Breast Cancer
MetaStat, Inc. Announces Positive Results of a MenaCalc(TM) Prognostic Study of Axillary Node-Negative Breast Cancer.
About this update from Metastat Inc
[{"type":"text","content":"\nMetaStat, Inc. Announces Positive Results of a MenaCalc(TM) Prognostic Study of Axillary Node-Negative Breast Cancer\n\nMetaStat, Inc. Announces Positive Results of a MenaCalc(TM) Prognostic Study of Axillary Node-Negative Breast Cancer\n\n\nFindings Reinforce the Value of MenaCalc(TM) as a Prognostic Marker for Survival in an Independent Patient Cohort and ANN Patient Population\n\n BOSTON, MA--(Marketwired - September 02, 2015) - MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing tissue-based diagnostic tests for prediction of cancer metastasis, today announced positive results by Forse et al., published in BioMed Central Cancer of their MenaCalc assay in patients with axillary node negative (ANN) invasive breast cancer. Data from this study confirmed earlier results that MenaCalc™ is a strong predictor of disease-specific overall survival in patients with node-negative invasive breast cancer (p=0.0199), and had good performance in a subset of patients who did not receive hormone or chemotherapy (p=0.0052). \"This study further demonstrates the importance of the MenaCalc™ biomarker in predicting patient outcome in breast cancer patients and, importantly, in node-negative patients where physicians need the most information for determining proper treatment regimens,\" says Mark Gustavson, PhD, Vice President of Diagnostics for Metastat. In this clinical study of 403 patients, 261 women received adjuvant treatment (chemotherapy and/or hormone therapy) and 142 did not. Women who had high MenaCalc™ scores had a 2.2-fold greater risk of death compared to patients with low MenaCalc™ (p=0.0199) when controlled for other traditional clinical factors. A similar association was found with the subgroup who did not receive adjuvant treatment (p=0.0353; n=142), but as expected, the association with patients who received adjuvant treatment was not significant, providing preliminary evidence that high MenaCalc™ patients may benefit from added therapy.About MenaCalc™MenaCalc™ is a quantitative immunofluorescent tissue-based assay which measures expression levels of the Mena protein and its non-invasive isoform Mena11A. The MenaCalc™ diagnostic platform is prognostic for metastatic risk and has the potential to predict outcome in multiple epith...